MITCHELL DEAN J 4

What Happened

• Dean J. Mitchell, a director of Praxis Precision Medicines, was granted 1,371 restricted stock units (RSUs) and an additional 648 derivative share awards on June 10, 2026. Both grants were reported as acquisitions at $0.00 (no cash paid).
• The 1,371 RSUs are a contingent right to receive one share of common stock per unit and will be settled by delivery of shares when they vest. The 648-share award is a derivative award with a monthly vesting schedule described below.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (timely filing, two days after transaction).
• Grant amounts and prices: 1,371 RSUs @ $0.00; 648 derivative awards @ $0.00.
• Vesting:
  • 1,371 RSUs vest in a single installment on the earlier of June 10, 2027 or the date of the 2027 annual meeting.
  • The 648-share award vests in 12 equal monthly installments on the 10th of each month starting July 10, 2026 and ending on the earlier of June 10, 2027 or the 2027 annual meeting.
• Settlement: The 1,371 RSUs may be settled only by delivering common stock. The derivative award vests into shares per the schedule above.
• Shares owned after the grants: not specified in the provided filing excerpt.
• No sale or purchase for cash occurred; these are compensation awards (transaction code A).

Context

• Awards like RSUs are compensation and do not represent an immediate open-market purchase or sale; they convert into shares only as they vest and are settled.
• These grants do not by themselves indicate immediate insider buying or selling activity — they reflect equity compensation and will only affect shareholdings when vested/settled.